Silo Pharma Inc. said the Canadian Intellectual Property Office has allowed its patent application for SPC-15, an intranasal 5-HT4 receptor agonist being developed to prevent or delay stress-induced psychiatric disorders such as post-traumatic stress disorder.
The patent allowance covers methods of administering serotonin 4 receptor agonists prior to a stressor to reduce subsequent fear and depressive-like behavior, according to the company. Silo holds an exclusive license for the Canadian application as part of a broader agreement with Columbia University to develop, manufacture and commercialize SPC-15 globally.
SPC-15 is the lead asset in Silo’s pipeline, which also includes SP-26 for fibromyalgia and chronic pain, and a preclinical program targeting Alzheimer’s disease. The company’s wholly owned subsidiary QwikAgents provides managed AI agent services for research, content generation, scheduling and workflow automation.
The Canadian allowance follows recent intellectual property grants in other markets, including a European patent covering the same invention. Silo has indicated it plans to pursue regulatory pathways including the FDA’s 505(b)(2) route for SPC-15.
